https://www.live-feeds.com/feed/moderna-and-merck-say-mrna-cancer-vaccine-succeeded-in-late-stage-melanoma-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-and-merck-say-mrna-cancer-vaccine-succeeded-in-late-stage-melanoma-trialhttps://www.live-feeds.com/feed/moderna-and-merck-say-mrna-cancer-vaccine-succeeded-in-late-stage-melanoma-trial#u47583Mon, 24 Aug 2026 13:23:03 +0000Moderna and Merck announced Wednesday that an experimental personalized mRNA vaccine kept melanoma from returning or spreading in high-risk patients. The phase 3 clinical trial involved more than 1,000 participants. This treatment pairs a neoantigen vaccine with the immunotherapy drug pembrolizumab to target tumors specific to each patient. The trial marks the final clinical stage required before the companies can apply for FDA approval. Following the news, Moderna shares rose over 170 percent in one session.Why it mattersPersonalized vaccines represent a shift toward therapies tailored to an https://www.live-feeds.com/feed/moderna-and-merck-say-mrna-cancer-vaccine-succeeded-in-late-stage-melanoma-trialhttps://www.live-feeds.com/feed/moderna-and-merck-say-mrna-cancer-vaccine-succeeded-in-late-stage-melanoma-trial#u46232Sat, 22 Aug 2026 07:36:02 +0000Moderna and Merck developed a personalized mRNA cancer vaccine that significantly reduced melanoma recurrence during a phase 3 clinical trial. The treatment combines a neoantigen vaccine with the immunotherapy drug pembrolizumab. This success marks the final clinical step before the companies can seek FDA approval. Following the announcement, Moderna shares surged more than 170 percent in a single session. The trial results suggest the treatment could lead to a new generation of therapies tailored to the specific tumors of individual patients.Why it mattersMelanoma is a dangerous form of skin https://www.live-feeds.com/feed/moderna-and-merck-say-mrna-cancer-vaccine-succeeded-in-late-stage-melanoma-trialhttps://www.live-feeds.com/feed/moderna-and-merck-say-mrna-cancer-vaccine-succeeded-in-late-stage-melanoma-trial#u45477Thu, 20 Aug 2026 06:34:43 +0000Moderna and Merck reported that their mRNA cancer vaccine succeeded in a late-stage clinical trial for melanoma. The announcement triggered a massive surge in Moderna stock, with reports on the increase varying from 60% to a doubling of the share price. This development suggests the vaccine shows promise in treating advanced skin cancer, marking a potential shift in cancer treatment methodologies. The companies are positioning the results as a success in the late-stage testing phase.Why it mattersThe vaccine utilizes mRNA technology, the same platform used for COVID-19 vaccines, to target canc